Aditxt, Inc.
About Aditxt, Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.2K
- Net income
- -$43.1M
- Total assets
- $16.5M
- Market cap
- $50.7K
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $50.7K
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 30, 2020
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Aditxt, Inc..
